Alexander F.
- Country
- Norway
- Department
- Department for cancer treatment
Research Overview
- Evaluation of Epcoritamab in Combination with Chemotherapeutic Agents in B-cell Non-Hodgkin Lymphoma: A Phase 1b/2 Open-Label Study
- Evaluation of Subcutaneous Daratumumab in Patients with Moderate to Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Phase 3 Randomized Open-Label Trial of Epcoritamab Versus Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Data & Insights
Has run more than one trial at 46 of 297 partner sites.
Specializations
Lymphoma Research
This investigator specializes in the treatment of various forms of B-cell lymphomas, with particular emphasis on innovative therapeutic approaches for both newly diagnosed and relapsed/refractory cases.
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Classical Hodgkin Lymphoma
- Advanced Stage Lymphomas
The research focus includes evaluation of novel antibody-based therapies and combination treatment strategies.
Novel Therapeutics
Primary interest in developing and evaluating targeted immunotherapy approaches, particularly involving antibody-drug conjugates and innovative biological agents.
- Epcoritamab-based Combinations
- Brentuximab Vedotin Studies
- Zilovertamab Vedotin Research
Exploration of treatment options for patients who have failed conventional therapies.
Emerging Applications
Investigation of novel applications for established therapeutic agents in non-traditional treatment areas, including chronic conditions.
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Plasma Cell-Targeting Approaches
- Alternative Treatment Protocols
Focus on reducing treatment-related morbidity while maintaining therapeutic efficacy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.